.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,241,662

« Back to Dashboard

Claims for Patent: 8,241,662

Title:Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Inventor(s): Ebert; Charles D. (Salt Lake City, UT), Sanders; Steven W. (Salt Lake City, UT)
Assignee: Watson Laboratories, Inc. (Salt Lake City, UT)
Application Number:11/645,076
Patent Claims: 1. A method of treating a patient with an overactive bladder comprising the step of topically applying an unoccluded topical oxybutynin gel formulation to an outer skin surface of the patient's chest, torso, abdomen, arms or thighs once a day wherein the unoccluded topical gel formulation consists of: (i) a therapeutically effective amount of oxybutynin free base, oxybutynin chloride or a mixture of oxybutynin free base and oxybutynin chloride; (ii) about 1 wt % to about 30 wt. % water; (iii) about 0.05 wt % to about 10 wt. % gelling agent selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylethyl cellulose, hydroxypropylbutyl cellulose, hydroxypropylpentyl cellulose, hydroxyethyl cellulose, ethylcellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose phthalate, cellulose acetate and mixtures or copolymers thereof; (iv) at least 40 wt. % of a solvent selected from the group consisting of lower alcohols, C.sub.4-C.sub.10 mono-alcohols and mixtures thereof; (v) optionally up to about 10 wt. % emollient selected from the group consisting of fatty alcohols of about 12 to 20 carbon atoms, fatty acid esters having about 12 to 20 carbon atoms in the fatty acid moiety, petrolatum, mineral oils, soybean oil, sesame oil, almond oil, aloe vera gel, glycerol, allantoin and mixtures thereof; (vi) optionally a pH additive selected from the group consisting of methylamine, ethylamine, dialkylamines, trialkylamines, alkanolamines, dialkanolamines, triethanolamine, carbonic acid, acetic acid, oxalic acid, citric acid, tartaric acid, succinic acid, phosphoric acid, sodium or potassium salts thereof, hydrochloric acid, sodium hydroxide, ammonium hydroxide and mixtures thereof; and (viii) optionally a permeation enhancer; to provide a plasma area under the curve (AUC) ratio of oxybutynin to N-desethyloxybutynin of from about 0.5:1 to about 5:1, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said treatment.

2. The method of claim 1, wherein the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 1:1 to about 5:1.

3. The method of claim 1, wherein the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.8:1 to about 1.5:1.

4. The method of claim 1, wherein the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.5:1 to about 4:1.

5. A method of treating with oxybutynin a subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of administering to the outer skin surface of the subject an unoccluded topical gel formulation comprising: (i) a therapeutically effective amount of oxybutynin free base, oxybutynin chloride or a mixture of oxybutynin free base and oxybutynin chloride; (ii) about 0.05 wt. % to about 10 wt. % of a gelling agent; (iii) about 1 wt. % to about 30 wt. % water; (iv) at least about 40 wt. % of a solvent selected from the group consisting of lower alcohols, C.sub.4-C.sub.10 mono-alcohols and mixtures thereof; and (v) optionally a permeation enhancer; to provide a plasma area under the curve (AUC) ratio of oxybutynin to N-desethyloxybutynin of from about 0.5:1 to about 5:1.

6. The method of claim 5, wherein the solvent is present in an amount of at least about 70 wt. %.

7. The method of claim 5, wherein the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 1:1 to about 5:1.

8. The method of claim 5, wherein the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.8:1 to about 1.5:1.

9. The method of claim 5, wherein the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.5:1 to about 4:1.

10. The method of claim 5, wherein the unoccluded topical gel formulation is administered to an area on the subject from the group consisting of the subject's chest, torso, abdomen, arm, thigh and combinations thereof.

11. The method of claim 1, wherein the lower alcohol or C.sub.4-C.sub.10 mono-alcohol is selected from the group consisting of ethanol, isopropanol, benzyl alcohol, propanol, methanol and mixtures thereof.

12. The method of claim 1, wherein the solvent is ethanol.

13. The method of claim 5, wherein the lower alcohol or C.sub.4-C.sub.10 mono-alcohol is selected from the group consisting of ethanol, isopropanol, benzyl alcohol, propanol, methanol and mixtures thereof.

14. The method of claim 5, wherein the solvent is ethanol.

15. The method of claim 1, wherein the oxybutynin is oxybutynin chloride and the gelling agent is hydroxypropyl cellulose, the solvent is ethanol, the emollient is glycerol and the pH additive is sodium hydroxide.

16. The method of claim 5, wherein the oxybutynin is oxybutynin chloride and the gelling agent is hydroxypropyl cellulose.

17. The method of claim 1, wherein the permeation enhancer is selected from the group consisting of fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid, fatty acid esters of glycolic acid, glycerol triester, glycerol diester, glycerol monoester, triacetin, short chain alcohols and mixtures thereof.

18. The method of claim 5, wherein the permeation enhancer is selected from the group consisting of fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid, fatty acid esters of glycolic acid, glycerol triester, glycerol diester, glycerol monoester, triacetin, short chain alcohols and mixtures thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc